GlassScriptPhysician profile
Paul R Smith
NPI 1912093964
$10,007.56
in general payments reported to CMS, 2019-2025
52 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $1,392 · 2021: $1,766 · 2022: $1,336 · 2023: $1,754 · 2024: $1,217 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,548.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.25 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $941.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $939.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $849.01 | 2019-2025 | Saphnelo, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $847.76 | 2019-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $426.12 | 2021-2025 | |
| Glaxosmithkline, LLC. | $415.31 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $376.40 | 2020-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $357.38 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $333.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.74 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $321.29 | 2019-2025 | Veozah |
| Esperion Therapeutics, INC. | $293.81 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $262.00 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $251.60 | 2023-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.